About

Ahmad Shabsigh is a leading urologic oncologist whose research has fundamentally shaped the modern surgical management of bladder and kidney cancers, with a particular focus on the comparative effectiveness of robotic versus open surgery. He is best known as a principal investigator of the landmark RAZOR trial (760 citations), the first multi-institutional, randomized phase 3 study to demonstrate that robot-assisted radical cystectomy is non-inferior to open surgery for progression-free survival in bladder cancer patients. This seminal work, along with subsequent analyses on 3-year outcomes (115 citations) and health-related quality of life (34 citations), has provided crucial evidence for surgical decision-making. Dr. Shabsigh has also pioneered robotic techniques for complex renal cell carcinoma, leading the largest multi-institutional series on robotic nephrectomy with inferior vena cava tumor thrombectomy (100 citations). His research extends to evaluating functional recovery after cystectomy and the physiological effects of surgical positioning. With over 1,100 cumulative citations, his work continues to drive innovation and evidence-based practice in minimally invasive urologic oncology.

Research Focus

Key Achievements

8
H-Index
14
Papers
1,198
Total Citations
86
Avg Citations/Paper
🏆 Most Cited Paper
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
760 citations · 2018
📈 Most Prolific Year: 2019 (2 Papers)
🤝 Key Collaborators: 75
🏛 Institutions: The Ohio State University, The Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus Oncology and Hematology Associates

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago